Toll-like receptors as therapeutic targets in cystic fibrosis.
journal contributionposted on 2022-01-17, 16:12 authored by Catherine GreeneCatherine Greene, Peter BranaganPeter Branagan, Noel G McElvaneyNoel G McElvaney
Background: Toll-like receptors (TLRs) are pattern recognition receptors that act as a first-line of defence in the innate immune response by recognising and responding to conserved molecular patterns in microbial factors and endogenous danger signals. Cystic fibrosis (CF)-affected airways represent a milieu potentially rich in TLR agonists and the chronic inflammatory phenotype evident in CF airway epithelial cells is probably due in large part to activation of TLRs. Objective/methods: To examine the prospects of developing novel therapies for CF by targeting TLRs. We outline the expression and function of TLRs and explore the therapeutic potential of naturally-occurring and synthetic TLR inhibitors for CF. Results/conclusion: Modulation of TLRs has therapeutic potential for the inflammatory lung manifestations of CF.
Published CitationThis article is also available at http://informahealthcare.com/
- Beaumont Hospital